The Liver Meeting 2019-Current Therapies - Guidelines, Pitfalls and the "Gray Zone"

Current Therapies - Guidelines, Pitfalls and the "Gray Zone"

Video Transcription

Video Summary

The speaker discusses the current landscape of hepatitis B treatment, focusing on the challenges and gray areas in therapy. They highlight the importance of targeting high-risk individuals and aiming for outcomes like undetectable HPV DNA and surface antigen loss. The speaker emphasizes the need for personalized treatment approaches, especially for patients in the "gray zone" who don't fit typical treatment criteria. They touch on the controversy surrounding treating immune-tolerant patients and the potential impact on reducing liver cancer risk. The discussion also includes preferred oral therapies and recent studies suggesting differential effects on hepatocellular carcinoma risk between antiviral medications. Overall, the talk underscores the complexity of hepatitis B treatment decisions and the evolving understanding of optimal management strategies.

Asset Caption

Presenter: Norah Terrault

Keywords

hepatitis B treatment

challenges in therapy

high-risk individuals

personalized treatment approaches

antiviral medications